Fennec Pharmaceuticals Inc. (FENC) Bundle
Understanding Fennec Pharmaceuticals Inc. (FENC) Revenue Streams
Understanding Fennec Pharmaceuticals Inc.’s Revenue Streams
Fennec Pharmaceuticals Inc. (FENC) has shown significant growth in its revenue streams for the year 2024. The primary sources of revenue for the company are product sales and licensing revenue.
Revenue Breakdown
- Product Sales: For the nine-month period ended September 30, 2024, net product sales amounted to $21,655,000, an increase from $11,517,000 for the same period in 2023.
- Licensing Revenue: The company recorded $17,958,000 in licensing revenue during the same period, with no licensing revenue reported in the previous year.
| Revenue Source | September 30, 2024 (in $) | September 30, 2023 (in $) | Change (in $) |
|---|---|---|---|
| Product Sales, Net | 21,655,000 | 11,517,000 | 10,138,000 |
| Licensing Revenue | 17,958,000 | 0 | 17,958,000 |
| Total Net Revenue | 39,613,000 | 11,517,000 | 28,096,000 |
Year-over-Year Revenue Growth Rate
The year-over-year revenue growth rate for the nine-month period shows a substantial increase:
- Total Revenue Growth: The total net revenue increased from $11,517,000 in 2023 to $39,613,000 in 2024, reflecting a growth rate of approximately 243%.
- Product Sales Growth: Net product sales saw a growth of 88% from $11,517,000 to $21,655,000.
- Licensing Revenue: The introduction of licensing revenue contributed significantly, with a total of $17,958,000 recognized in 2024.
Contribution of Different Business Segments to Overall Revenue
As of September 30, 2024, the contribution of each segment to the overall revenue was as follows:
- Product Sales: 55% of total revenue
- Licensing Revenue: 45% of total revenue
Analysis of Significant Changes in Revenue Streams
The most notable change in revenue streams is the introduction of licensing revenue, which has significantly impacted total revenue. This shift indicates a diversification of revenue sources, moving from primarily product sales to a more balanced approach that includes licensing agreements.
In summary, the financial performance of Fennec Pharmaceuticals Inc. in 2024 showcases robust growth in both product sales and licensing revenues, positioning the company favorably for future financial stability.
A Deep Dive into Fennec Pharmaceuticals Inc. (FENC) Profitability
Profitability Metrics
Gross Profit Margin: For the nine months ended September 30, 2024, the company reported a gross profit of $21,655 on net product sales, resulting in a gross profit margin of approximately 54.6%. In comparison, for the nine months ended September 30, 2023, it reported a gross profit of $11,517 on net product sales, yielding a gross profit margin of about 47.8%.
Operating Profit: The operating loss for the nine months ended September 30, 2024 was $3,502, a significant improvement from an operating loss of $10,953 for the same period in 2023. This indicates a narrowing of the loss, suggesting improved operational efficiency.
Net Profit Margin: The net loss for the nine months ended September 30, 2024 was $1,549, translating to a net profit margin of approximately 3.9% when compared to total net revenue of $39,613. For the nine months ended September 30, 2023, the net loss was $13,363, resulting in a net profit margin of about (116.0%).
Trends in Profitability Over Time
The following table summarizes the trends in profitability metrics over the past two years:
| Metric | September 30, 2024 | September 30, 2023 | Change |
|---|---|---|---|
| Gross Profit | $21,655 | $11,517 | $10,138 |
| Gross Profit Margin | 54.6% | 47.8% | 6.8% |
| Operating Profit (Loss) | ($3,502) | ($10,953) | $7,451 |
| Net Profit (Loss) | ($1,549) | ($13,363) | $11,814 |
Comparison of Profitability Ratios with Industry Averages
As of 2024, the average gross profit margin in the biotechnology industry is approximately 70%. The reported gross profit margin of 54.6% indicates that the company is slightly below the industry average. However, the trend shows improvement, as it increased from 47.8% in 2023.
The average operating margin for biotech firms typically hovers around 20%. The company’s significant operating loss of ($3,502) reflects a need for continued focus on cost management and revenue generation.
Analysis of Operational Efficiency
Cost Management: Total operating expenses for the nine months ended September 30, 2024, were $36,111, up from $22,470 in 2023. This increase is primarily driven by higher selling and marketing expenses, which rose to $14,482 from $8,255.
Gross Margin Trends: The gross margin trend illustrates a positive trajectory, increasing by 6.8% year-over-year. This suggests that while operating expenses have increased, the company has been effective in enhancing its revenue-generating capabilities.
Net Income Trends: The net loss has decreased significantly from $13,363 in 2023 to $1,549 in 2024, indicating improved operational efficiency and better management of expenses relative to revenue.
Debt vs. Equity: How Fennec Pharmaceuticals Inc. (FENC) Finances Its Growth
Debt vs. Equity: How Fennec Pharmaceuticals Inc. Finances Its Growth
Debt Levels:
As of September 30, 2024, the total liabilities of the company amounted to $64,092,000. This includes current liabilities of $7,435,000 and non-current liabilities of $56,657,000. The long-term debt consists mainly of a term loan of $30,000,000 with additional PIK interest of $2,323,000.
Debt-to-Equity Ratio:
The debt-to-equity ratio stands at 12.38, calculated from total liabilities of $64,092,000 and total stockholders' deficit of ($5,171,000). This ratio significantly exceeds the industry average of approximately 1.5 for biotechnology firms, indicating a heavy reliance on debt financing.
Recent Debt Issuances:
In 2022, the company entered into a Securities Purchase Agreement with Petrichor Opportunities Fund I LP for up to $45,000,000 in senior secured floating rate convertible notes. The company has drawn down $30,000,000 of this facility across three tranches, with the most recent tranche of $5,000,000 closed on December 4, 2023.
Credit Ratings:
As of September 30, 2024, the company does not have a formal credit rating from major agencies. However, the financial health is reflected in the terms of its debt financing, which include a commitment fee of 2.0% on the notes issued.
Balancing Debt and Equity:
The company has made efforts to balance its debt financing with equity funding. As of September 30, 2024, common stock and additional paid-in capital amounted to $211,282,000. The company also reported an increase in cash and equivalents to $40,320,000 from $13,269,000 at the end of the previous year, indicating a strategic focus on liquidity.
| Financial Metric | Value (USD) |
|---|---|
| Total Liabilities | $64,092,000 |
| Current Liabilities | $7,435,000 |
| Long-term Debt | $30,000,000 |
| Debt-to-Equity Ratio | 12.38 |
| Common Stock and Additional Paid-in Capital | $211,282,000 |
| Cash and Equivalents | $40,320,000 |
Assessing Fennec Pharmaceuticals Inc. (FENC) Liquidity
Assessing Fennec Pharmaceuticals Inc.'s Liquidity
Current Ratio: As of September 30, 2024, the current ratio was calculated as follows:
- Current Assets: $57,965 (Cash and equivalents: $40,320 + Other current assets: $17,645)
- Current Liabilities: $7,435
- Current Ratio: 7.79
Quick Ratio: The quick ratio, which excludes inventory from current assets, is:
- Current Assets (excluding inventory): $57,965
- Current Liabilities: $7,435
- Quick Ratio: 7.79
Working Capital Trends: The working capital increased significantly from December 31, 2023, to September 30, 2024:
- Working Capital (September 30, 2024): $50,530
- Working Capital (December 31, 2023): $19,305
- Increase in Working Capital: $31,225
Cash Flow Statements Overview
The cash flow statements for the nine-month periods ending September 30, 2024, and 2023 show the following:
| Cash Flow Data | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net cash provided by operating activities | $28,454 | ($12,283) |
| Net cash provided by investing activities | $0 | $0 |
| Net cash (used in) provided by financing activities | ($1,403) | $908 |
| Total net cash flow | $27,051 | ($11,375) |
Cash Flow Analysis: The cash flow from operating activities turned positive in 2024, significantly improving from a negative cash flow in 2023. This positive cash flow is attributed to:
- Cash inflows from product sales: $8,923
- Cash inflows from licensing agreements: $43,200
- Cash inflows from option exercises: $1,131
Potential Liquidity Concerns or Strengths
As of September 30, 2024, the company demonstrated a strong liquidity position with total cash and cash equivalents of $40,320 compared to $13,269 on December 31, 2023. The total current liabilities decreased slightly from $7,553 to $7,435.
The accumulated deficit stood at ($217,696) as of September 30, 2024, indicating ongoing operational losses. However, the significant increase in cash reserves and working capital suggests that the company is effectively managing its liquidity amidst operational challenges.
This liquidity strength is further highlighted by the positive trend in cash flows and the current and quick ratios, both of which suggest a robust capacity to meet short-term obligations.
Is Fennec Pharmaceuticals Inc. (FENC) Overvalued or Undervalued?
Valuation Analysis
To determine whether Fennec Pharmaceuticals Inc. is overvalued or undervalued, we will analyze key financial metrics, including the price-to-earnings (P/E), price-to-book (P/B), and enterprise value-to-EBITDA (EV/EBITDA) ratios, alongside stock price trends and analyst consensus.
Price-to-Earnings (P/E) Ratio
The P/E ratio is a critical indicator for assessing the valuation of a company. As of September 30, 2024, Fennec Pharmaceuticals reported a net loss of $1,549,000 for the nine months ended September 30, 2024. With a weighted average number of common shares outstanding of 27,371, the basic net loss per share is $(0.21). Given that the company has incurred losses, the P/E ratio is not applicable for this period.
Price-to-Book (P/B) Ratio
The P/B ratio is another important valuation metric. As of September 30, 2024, the total stockholders’ deficit was $(5,171,000). The book value per share can be derived by dividing the total equity by the number of shares outstanding. With 27,422 shares outstanding, the book value per share is approximately $(0.19), indicating a P/B ratio that is also not applicable due to the negative book value.
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The EV/EBITDA ratio provides insight into the company's overall valuation compared to its earnings before interest, taxes, depreciation, and amortization. As of September 30, 2024, the enterprise value can be calculated as follows:
- Market Capitalization: Not directly available due to a negative equity position.
- Total Debt: $30,000,000.
- Cash and Cash Equivalents: $40,320,000.
With a negative EBITDA reported from operations, the EV/EBITDA ratio cannot be computed meaningfully at this time.
Stock Price Trends
Over the last 12 months, the stock price of Fennec Pharmaceuticals has shown fluctuations. As of September 30, 2024, the stock price was approximately $7.89, with a 52-week high of $12.00 and a low of $5.00. This indicates a volatility in the stock's performance, reflecting investor sentiment and market conditions.
Dividend Yield and Payout Ratios
Fennec Pharmaceuticals has not declared any dividends, resulting in a dividend yield of 0%. Consequently, the payout ratio is also not applicable as there are no earnings distributed to shareholders.
Analyst Consensus
Analysts currently have mixed views on the stock's valuation. The consensus rating is a Hold based on the company's potential for future growth against its current financial challenges. Analysts have noted the need for continued monitoring of operational performance and market conditions.
| Metric | Value |
|---|---|
| P/E Ratio | N/A |
| P/B Ratio | N/A |
| EV/EBITDA Ratio | N/A |
| Stock Price (as of Sep 30, 2024) | $7.89 |
| 52-Week High | $12.00 |
| 52-Week Low | $5.00 |
| Dividend Yield | 0% |
| Analyst Consensus | Hold |
Key Risks Facing Fennec Pharmaceuticals Inc. (FENC)
Key Risks Facing Fennec Pharmaceuticals Inc.
The financial health of Fennec Pharmaceuticals Inc. is influenced by a variety of internal and external risks that could impact its operations and market performance. Below is a detailed breakdown of these risks as of 2024.
Industry Competition
The pharmaceutical industry is highly competitive, with numerous companies vying for market share in oncology and pediatric therapeutics. The presence of established players poses a significant threat. For instance, Fennec competes against companies offering alternative therapies for conditions treated with PEDMARK, its primary product, which can potentially limit market penetration.
Regulatory Changes
Fennec Pharmaceuticals operates under stringent regulations set by entities such as the FDA. Any changes in regulatory requirements can impose additional costs and delays in product development. For example, the adoption of new accounting standards, such as ASU No. 2023-09, which is set for implementation in 2025, could affect financial disclosures.
Market Conditions
Economic fluctuations and market conditions can greatly influence revenue streams. For the nine months ended September 30, 2024, the company reported net product sales of $21,655 compared to $11,517 in the same period of 2023, showcasing growth but also indicating reliance on market stability. Moreover, the company’s licensing revenue reached $17,958 in 2024, marking a significant increase from the previous year.
Operational Risks
- Increased operational costs have been noted, with total operating expenses for the nine months ending September 30, 2024, at $36,111, compared to $22,470 the previous year.
- The company has experienced a net loss of $1,549 for the nine months ended September 30, 2024.
Financial Risks
Fennec Pharmaceuticals has a substantial accumulated deficit of $217,696 as of September 30, 2024. This raises concerns about the company's ability to sustain operations without additional financing. Additionally, the company has a term loan of $30,000, which poses a financial obligation that could impact cash flow.
Strategic Risks
The potential need for additional financing is a critical strategic risk. The company is currently exploring various strategic alternatives, including collaborations with other pharmaceutical companies to mitigate cash flow risks.
Mitigation Strategies
To address these risks, Fennec Pharmaceuticals is focusing on expanding its market outreach and enhancing operational efficiencies. The company has reported positive cash flows from operating activities amounting to $28,454 for the nine months ended September 30, 2024, indicating a proactive approach to managing operational expenditures.
| Risk Category | Description | Current Impact |
|---|---|---|
| Industry Competition | High competition in oncology therapeutics. | Potential market share dilution. |
| Regulatory Changes | Changes in FDA regulations affecting drug approval processes. | Increased compliance costs. |
| Market Conditions | Economic fluctuations affecting sales. | Revenue variability. |
| Operational Risks | Increased operational costs and net losses. | Pressure on financial health. |
| Financial Risks | High accumulated deficit and loan obligations. | Risk of insolvency without additional financing. |
| Strategic Risks | Need for collaborations and partnerships. | Dependence on external funding sources. |
Future Growth Prospects for Fennec Pharmaceuticals Inc. (FENC)
Future Growth Prospects for Fennec Pharmaceuticals Inc.
Analysis of Key Growth Drivers
The company has identified several key growth drivers that will shape its future trajectory:
- Product Innovations: The FDA-approved product, PEDMARK®, aims to reduce the risk of ototoxicity associated with cisplatin in pediatric patients. The successful launch and market penetration of PEDMARK have been significant milestones.
- Market Expansions: The company has made strides in expanding its market reach, particularly in Europe, where PEDMARK is marketed as PEDMARQSI. The licensing agreement with Norgine is expected to enhance distribution capabilities and revenue streams.
- Acquisitions: Strategic partnerships and potential acquisitions are being explored to bolster the product portfolio and expand into new therapeutic areas.
Future Revenue Growth Projections and Earnings Estimates
For the nine months ended September 30, 2024, the company recorded total net revenue of $39,613 thousand, compared to $11,517 thousand for the same period in 2023, marking an increase of $28,096 thousand.
Projected revenue is anticipated to continue growing due to:
- Increased product sales, which reached $21,655 thousand for the nine months ended September 30, 2024, up from $11,517 thousand in 2023.
- Licensing revenue of $17,958 thousand generated during the same period, which was non-existent in the prior year.
Strategic Initiatives or Partnerships
The company is actively pursuing collaborations to enhance its market presence. The licensing agreement with Norgine has already provided a significant influx of cash, with a total cash inflow of $43,200 thousand from the deal.
Additional strategic initiatives include:
- Expanding outreach to community oncology centers and targeting the adolescent and young adult (AYA) population.
- Increasing marketing expenditures, which totaled $14,482 thousand for the nine months ended September 30, 2024, compared to $8,255 thousand in 2023.
Competitive Advantages
The company possesses several competitive advantages that position it favorably for future growth:
- Unique Product Offering: PEDMARK addresses a critical need in pediatric oncology, providing a niche market opportunity.
- Strong Financial Position: As of September 30, 2024, cash and cash equivalents stood at $40,320 thousand, significantly improved from $13,269 thousand at December 31, 2023, indicating robust liquidity.
- Positive Cash Flow: The company reported positive cash flows from operating activities of $28,454 thousand for the nine months ended September 30, 2024, compared to a cash outflow of $(12,283) thousand in 2023.
| Financial Metrics | Q3 2024 | Q3 2023 | Year-over-Year Change |
|---|---|---|---|
| Total Net Revenue | $39,613 thousand | $11,517 thousand | $28,096 thousand |
| Product Sales | $21,655 thousand | $11,517 thousand | $10,138 thousand |
| Licensing Revenue | $17,958 thousand | $0 thousand | $17,958 thousand |
| Cash and Cash Equivalents | $40,320 thousand | $13,269 thousand | $27,051 thousand |
| Operating Cash Flow | $28,454 thousand | $(12,283) thousand | $40,737 thousand |
Fennec Pharmaceuticals Inc. (FENC) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Fennec Pharmaceuticals Inc. (FENC) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Fennec Pharmaceuticals Inc. (FENC)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Fennec Pharmaceuticals Inc. (FENC)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.